TRANSFORM
THE PARADIGM

Joshua Brumm joined Crescent as chief executive officer (CEO) in March 2025, bringing extensive experience in building and leading companies in biotech and healthcare. Previously, he was a general partner at Forbion, and from 2019 to 2024, he was president and CEO of Dyne Therapeutics, where he led the company through its initial public offering (IPO) and advanced two rare muscle disease programs to positive data demonstrating clinical proof-of-concept. Prior to that, he served as chief operating officer (COO) and chief financial officer (CFO) of Kaleido Biosciences as well as Versartis, leading both companies through their IPOs while progressing their product candidates through clinical development. His previous roles include serving as executive vice president of finance and principal financial officer at Pharmacyclics, an oncology company that was ultimately acquired by AbbVie; CFO at ZELTIQ Aesthetics, where he led the company through its IPO and the international product launch for CoolSculpting; and director of finance at Proteolix, an oncology company, assisting in its sale to Onyx Pharmaceuticals. He also held investment banking positions at Citigroup Global Markets and Morgan Stanley.

Over the course of his career, Mr. Brumm has led four companies to their public listings, held senior leadership positions in three companies that were acquired and raised nearly $3 billion in capital. He currently serves on the board of AIRNA, is chairman of the board of Amphista Therapeutics and is a venture partner at Forbion, a leading life sciences investment firm. Mr. Brumm holds a BA in business administration from the University of Notre Dame.

Jonathan McNeill, M.D. joined Crescent as president and chief operating officer in March 2025, bringing extensive experience in corporate strategy, business development and financing in multiple therapeutic areas, including oncology and rare disease. Previously, he was at Dyne Therapeutics for more than five years, most recently as chief business officer, where he led business development, executed multiple financings totaling more than $1 billion and was a key member of the executive team that advanced two neuromuscular disease programs through clinical proof-of-concept trials. Prior to that, Dr. McNeill served on the business development team at Editas Medicine where he played a key role in the execution of the company’s initial public offering and its oncology collaboration with Juno Therapeutics. Dr. McNeill was previously a member of Boston Consulting Group’s healthcare practice. He currently serves as a Venture Partner at Forbion, a leading life sciences investment firm. Dr. McNeill earned his BA in public policy and economics from the University of North Carolina and his M.D. from the University of Pennsylvania.

Ellie Im, M.D. joined Crescent as chief medical officer in April 2025, bringing deep experience in oncology clinical development and operations across different modalities, including ADCs and bispecific antibodies. Most recently, Dr. Im was senior vice president of clinical development at Centessa Pharmaceuticals where she oversaw clinical development, clinical pharmacology, biostatistics, project management and safety across multiple therapeutic areas, including oncology. Prior to joining Centessa, she was senior vice president, clinical development and operations at Mersana Therapeutics where she led teams in clinical development and clinical operations. Previously, Dr. Im was clinical development lead and senior medical director at Tesaro, an oncology-focused company that was later acquired by GlaxoSmithKline, where she led the clinical development for JEMPERLI^®. Earlier in her career, she served as medical director for Merck and led clinical development for KEYTRUDA^®. Dr. Im is a medical oncologist and holds an M.D. from Catholic University College of Medicine, South Korea. She is board certified in internal medicine and medical oncology, and a member of the American Society of Clinical Oncology and Hematology.

Rick Scalzo joined Crescent as chief financial officer in April 2025, bringing significant life science and public company finance experience. Previously, he spent more than five years at Dyne Therapeutics, most recently as senior vice president, head of finance and administration, overseeing several functions, including finance, accounting and facilities, leading the company’s transition to a public company and assisting in the execution of multiple financings. Prior to that, Mr. Scalzo served as corporate controller at Kaleido Biosciences, where he played a key role in the execution of the company’s initial public offering and led the accounting group’s transition from private to public company. Prior to joining Kaleido, he served as corporate controller at X4 Pharmaceuticals as well as Ocata Therapeutics. At Ocata, Mr. Scalzo was a significant contributor to the company’s acquisition by Astellas Pharma and the subsequent integration of the companies. He began his career in public accounting in the Health Industries practice at PricewaterhouseCoopers. Mr. Scalzo is a certified public accountant in the Commonwealth of Massachusetts, and received his BS in accounting from Boston College and his MBA from University of Massachusetts, Amherst.

Jan Pinkas, Ph.D., joined Crescent as chief scientific officer in July 2025, bringing more than two decades of experience in oncology drug development, leading preclinical and translational research with expertise in multiple modalities, including antibody-drug conjugates (ADCs). Prior to joining Crescent, Dr. Pinkas was chief scientific officer at Pyxis Oncology, where he established the preclinical research and development function to support ADC and antibody programs through Investigational New Drug (IND)-enabling studies and led the translational medicine group. Previously, at Magenta Therapeutics, Dr. Pinkas served as senior vice president, translational sciences, establishing a new department to support programs as the company advanced from preclinical research to late-stage clinical development. Prior to Magenta, Dr. Pinkas worked at ImmunoGen for more than 10 years in positions of increasing responsibility, most recently as vice president, translational research and development. In that role, he led groups supporting molecules from early-stage research to IND, and also advancing to pivotal clinical development, including contributing to ELAHERE^®, an ADC approved for the treatment of platinum-resistant ovarian cancer, as well as SARCLISA^®, an anti-CD38 therapy approved in combination with standard of care for multiple myeloma. Earlier in his career, he held scientist roles focused on oncology research at Amgen and Genzyme Corporation. Dr. Pinkas earned his Ph.D. in molecular and cellular biology at the University of Massachusetts, Amherst and received his BA in biology from Johns Hopkins University.

Barbara Bispham joined Crescent as general counsel and corporate secretary in January 2025. Prior to joining Crescent, she served as senior vice president, general counsel and corporate secretary at Sail Biomedicines, where she oversaw the company's legal and intellectual property operations. Prior to Sail, Ms. Bispham served as senior vice president, general counsel and corporate secretary at Senda Biosciences, a biotechnology company and subsidiary of Flagship Pioneering, until it merged with LARONDE, also a Flagship Pioneering subsidiary, to form Sail Biomedicines in October 2023. Prior to joining Senda, Ms. Bispham held positions of increasing responsibility at BridgeBio Pharma, most recently serving as vice president, head of legal, where she oversaw legal, transactional, employment, governance, litigation, privacy, compliance and intellectual property operations. While at BridgeBio Pharma, Ms. Bispham supported key activities in connection with the commercialization of the company's first two FDA-approved drugs, NULIBRY^® and TRUSELTIQ^®. Earlier, she was a member of Goodwin Procter LLP's Tech and Life Sciences Group and a corporate associate at Cooley LLP. Ms. Bispham earned her JD from Cornell Law School and her BA at the University of Pennsylvania.

Ryan Lynch has served as Crescent’s treasurer, senior vice president of finance and chief accounting officer since December 2024. Prior to joining Crescent, Mr. Lynch served as vice president of finance at Kelonia Therapeutics, where he was responsible for overseeing the company’s finance and accounting functions. Prior to Kelonia, Mr. Lynch served as senior director, corporate controller at Morphic Therapeutic, a biopharmaceutical company and wholly owned subsidiary of Morphic Holding, a Nasdaq-listed biopharmaceutical company that was acquired by Eli Lilly and Company in 2024, where he was responsible for overseeing the company’s finance and accounting functions. Prior to joining Morphic, Mr. Lynch held positions of increasing responsibility at Concert Pharmaceuticals from 2014 to 2019, most recently serving as senior director, corporate controller. Mr. Lynch received an MS in accounting from the University of Massachusetts Amherst and a BBA in accounting from the University of Massachusetts Amherst. Mr. Lynch is a licensed certified public accountant in Massachusetts.

Chris Doughty has served as chief business officer of Crescent since October 2024. Mr. Doughty previously was chief business officer of Prometheus Biosciences, serving in the role through its acquisition by Merck for $10.8 billion in 2023. He also served as vice president of strategy and business development at Strata Oncology, after working as a consultant at McKinsey & Company. Mr. Doughty earned an MBA and a BS in industrial and operations engineering from the University of Michigan.

Amy Reilly joined Crescent in March 2025 as chief communications officer, bringing nearly 25 years of experience in the life science industry to her role, including managing investor relations, executing pipeline and product communications, building employee communications and engagement programs and expanding corporate philanthropic initiatives. Most recently, Ms. Reilly was senior vice president, head of corporate communications and investor relations at Dyne Therapeutics where she helped execute the company’s initial public offering (IPO) and multiple financings totaling more than $1 billion, and oversaw pipeline and internal communications as well as digital and social media. Prior to that, Ms. Reilly was vice president, communications and investor relations at Kaleido Biosciences, where she supported the company’s IPO and managed executive and employee communications. She previously directed corporate communications at ImmunoGen, which was later acquired by AbbVie; led philanthropy and employee communications at Cubist Pharmaceuticals until its acquisition by Merck; and held various roles of increasing responsibility at Biogen. Ms. Reilly received her AB in English and American Literature from Bowdoin College.

Tanya Sengupta joined Crescent as executive vice president, chief of strategy and operations in April 2025, bringing extensive experience driving program and portfolio strategy and leading multi-disciplinary teams and functional organizations at all stages of drug development, launch and commercialization. Previously, she was at Dyne Therapeutics, most recently as senior vice president, head of portfolio strategy and operations where she was a key member of the executive team that advanced two neuromuscular disease programs through clinical proof-of-concept and registrational studies, overseeing program leadership and management, clinical operations, and new product planning.

Prior to joining Dyne Therapeutics, Ms. Sengupta was at Alnylam Pharmaceuticals for nine years where she contributed to the development of ONPATTRO^® and AMVUTTRA^®, established and led launch excellence in Europe, Canada, Middle East and Africa while overseeing the launches of ONPATTRO^®, GIVLAARI^® and OXLUMO^® in those regions, and led strategy and operations for the Asia Pacific region. Earlier in her career, Ms. Sengupta held various clinical operations positions at Vertex Pharmaceuticals and Wyeth, running registrational studies that led to the approvals of INCIVEK^®, TORISEL^® and XYNTHA^®/REFACTO AF^®.

Tanya started her career in academic research at the Dana-Farber Cancer Institute. She holds an MBA from Boston University Questrom School of Business and a BA from Amherst College.

Wenjie Cheng, Ph.D., has served as Crescent’s senior vice president of technical operations since February 2025, leading CMC strategy and overseeing manufacturing operations across the company’s therapeutic portfolio. Dr. Cheng brings more than 20 years of experience in the biopharmaceutical industry, with deep expertise in process development and manufacturing for antibody and antibody drug conjugate (ADC) therapeutics. She previously served as vice president, head of US development and manufacturing center at WuXi Biologics, where she was responsible for ensuring high-quality, scalable and regulatory-compliant bioprocesses for US-based clients and facilities. Before joining WuXi Biologics, Dr. Cheng held various leadership roles at ImmunoGen, a biotechnology company specializing in ADC therapeutics (acquired by AbbVie). She began her career as a scientist at Biogen. Dr. Cheng earned her Ph.D. and MS in biophysics from New York University and her BSc in applied chemistry at Shandong University.